About Cassava Sciences Inc
Cassava Sciences develops simufilam for Alzheimer's disease. Highly speculative biotech with binary clinical trial outcomes. No dividend, extreme volatility. Rich CSP premiums but existential FDA and legal risks. Only suitable for aggressive sellers with wide strikes who accept binary outcomes.
Biotechnology